{"slideshow_credits": null, "snippet": "Soaring stock prices and major advances in fighting diseases have some saying the industry has turned a corner and others watching for a bursting bubble.", "abstract": "Biotech industry is riding unprecedented wave of soaring stock prices and high rate of drug approvals, but executives and investors remain divided in their opinion of its future; some argue that industry has turned a corner in which high failure rate of new drugs has permanently declined, and that Big Pharma is set to take on new set of illnesses for first time; others remain skeptical, citing imminent bubble.", "section_name": "Technology", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2015/01/19/technology/riding-high-biotech-firms-remain-wary.html", "lead_paragraph": "Soaring stock prices and major advances in fighting diseases have some saying the industry has turned a corner and others watching for a bursting bubble.", "headline": {"main": "Riding High, Biotech Firms Remain Wary", "print_headline": "Riding High, Biotech Firms Remain Wary"}, "_id": "54bc59d138f0d86e1bcc8b52", "word_count": "1441", "multimedia": [{"height": 126, "url": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/01/19/business/pharmajump3/pharmajump3-articleLarge.jpg", "legacy": {"xlarge": "images/2015/01/19/business/pharmajump3/pharmajump3-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-01-19T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Biogen Idec Inc", "is_major": "N", "rank": "11"}, {"name": "organizations", "value": "bluebird bio Inc.", "is_major": "N", "rank": "12"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Stocks and Bonds", "is_major": "N", "rank": "3"}, {"name": "organizations", "value": "JPMorgan Chase & Company", "is_major": "N", "rank": "4"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Vertex Pharmaceuticals Inc", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Juno Therapeutics Inc", "is_major": "N", "rank": "8"}, {"name": "organizations", "value": "ZIOPHARM Oncology Inc", "is_major": "N", "rank": "9"}, {"name": "organizations", "value": "Intrexon Corporation", "is_major": "N", "rank": "10"}], "blog": [], "subsection_name": null, "type_of_material": "News"}